ATE242208T1 - Sulfonylharnstoff-derivate und ihre verwendung in der kontrolle der interleukin-1-aktivität - Google Patents

Sulfonylharnstoff-derivate und ihre verwendung in der kontrolle der interleukin-1-aktivität

Info

Publication number
ATE242208T1
ATE242208T1 AT97947201T AT97947201T ATE242208T1 AT E242208 T1 ATE242208 T1 AT E242208T1 AT 97947201 T AT97947201 T AT 97947201T AT 97947201 T AT97947201 T AT 97947201T AT E242208 T1 ATE242208 T1 AT E242208T1
Authority
AT
Austria
Prior art keywords
interleukin
activity
controlling
urea derivatives
sulfonyl urea
Prior art date
Application number
AT97947201T
Other languages
English (en)
Inventor
Mark Anthony Dombroski
James Frederick Eggler
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE242208T1 publication Critical patent/ATE242208T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/60—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT97947201T 1997-01-29 1997-12-29 Sulfonylharnstoff-derivate und ihre verwendung in der kontrolle der interleukin-1-aktivität ATE242208T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3697997P 1997-01-29 1997-01-29
PCT/IB1997/001603 WO1998032733A1 (en) 1997-01-29 1997-12-29 Sulfonyl urea derivatives and their use in the control of interleukin-1 activity

Publications (1)

Publication Number Publication Date
ATE242208T1 true ATE242208T1 (de) 2003-06-15

Family

ID=21891776

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02020749T ATE270285T1 (de) 1997-01-29 1997-12-29 4-substituiertes furan-2-sulfonamid und dessen verwendung in der herstellung von sulfonylharnstoff-derivate
AT97947201T ATE242208T1 (de) 1997-01-29 1997-12-29 Sulfonylharnstoff-derivate und ihre verwendung in der kontrolle der interleukin-1-aktivität

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT02020749T ATE270285T1 (de) 1997-01-29 1997-12-29 4-substituiertes furan-2-sulfonamid und dessen verwendung in der herstellung von sulfonylharnstoff-derivate

Country Status (40)

Country Link
US (2) US6166064A (de)
EP (1) EP0964849B1 (de)
JP (1) JP3573757B2 (de)
KR (1) KR100324058B1 (de)
CN (1) CN1127479C (de)
AP (1) AP929A (de)
AR (1) AR011093A1 (de)
AT (2) ATE270285T1 (de)
AU (1) AU723895B2 (de)
BG (1) BG103597A (de)
BR (1) BR9714328A (de)
CA (1) CA2279186C (de)
CO (1) CO4920230A1 (de)
CZ (1) CZ293173B6 (de)
DE (2) DE69722663T2 (de)
DK (2) DK0964849T3 (de)
DZ (1) DZ2407A1 (de)
EA (1) EA001803B1 (de)
ES (2) ES2222426T3 (de)
HR (1) HRP980045B1 (de)
HU (1) HUP0000567A3 (de)
ID (1) ID22223A (de)
IL (1) IL130855A0 (de)
IS (1) IS5099A (de)
MA (1) MA26468A1 (de)
NO (1) NO313279B1 (de)
NZ (1) NZ336248A (de)
OA (1) OA11079A (de)
PA (1) PA8444701A1 (de)
PE (1) PE57898A1 (de)
PL (1) PL335052A1 (de)
PT (2) PT964849E (de)
SK (1) SK283679B6 (de)
TN (1) TNSN98017A1 (de)
TR (1) TR199901816T2 (de)
TW (1) TW515788B (de)
UY (1) UY24861A1 (de)
WO (1) WO1998032733A1 (de)
YU (1) YU33799A (de)
ZA (1) ZA98685B (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022984A (en) * 1998-07-27 2000-02-08 Pfizer Inc. Efficient synthesis of furan sulfonamide compounds useful in the synthesis of new IL-1 inhibitors
EP1526383A3 (de) * 1998-08-31 2005-11-16 Pfizer Products Inc. Diarylsulphonylharnstoff-Bindungsproteine
IT1303249B1 (it) * 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
AU6464400A (en) * 1999-09-14 2001-04-17 Pfizer Products Inc. Combination treatment with il-1ra and diaryl sulphonyl urea compounds
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CA2369967A1 (en) * 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders
NZ530765A (en) 2001-06-26 2006-11-30 Amgen Fremont Inc Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
CA2459454A1 (en) 2001-09-14 2003-03-27 Bayer Pharmaceuticals Corporation Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists
MXPA04002565A (es) * 2001-11-30 2004-05-31 Pfizer Prod Inc Combinacion de un inhibidor de il-1/18 con un inhibidor de tnf para el tratamiento de inflamacion.
US20030131370A1 (en) * 2001-12-14 2003-07-10 Pfizer Inc. Disruption of the glutathione S-transferase-Omega-1 gene
RU2236677C2 (ru) * 2002-06-24 2004-09-20 Чичкова Марина Александровна Способ прогнозирования раннего клинического течения экссудативного перикардита у больных с системными заболеваниями
WO2004004725A2 (en) 2002-07-09 2004-01-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
ES2384379T3 (es) 2002-09-06 2012-07-04 Amgen, Inc. Anticuerpo monoclonal anti-IL-1R1 humano terapéutico
AU2003263560A1 (en) * 2002-10-03 2004-04-23 Pfizer Products Inc. Use of gst-omega-2 as a therapeutic target
AU2004263871B2 (en) 2003-08-06 2011-07-14 Senomyx, Inc. T1R hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds
DE602005016937D1 (de) * 2004-03-23 2009-11-12 Dompe Pha R Ma Spa Res & Mfg Pharmazeutische zusammensetzung
US20060045953A1 (en) * 2004-08-06 2006-03-02 Catherine Tachdjian Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
CN101384183B (zh) 2005-02-04 2012-07-04 西诺米克斯公司 包含连接有杂芳基部分的化合物及其作为用于食物组合物的新型鲜味调节剂、促味剂和味觉增强剂的应用
WO2006090932A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Managemant Co., Ltd. スルホンアミド化合物の代理マーカー
US7208526B2 (en) * 2005-05-20 2007-04-24 Hoffmann-La Roche Inc. Styrylsulfonamides
TW200715993A (en) 2005-06-15 2007-05-01 Senomyx Inc Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers
EP3398452B1 (de) 2006-04-21 2024-10-02 Firmenich Incorporated Essbare zusammensetzungen mit hochpotenten schmackhaften geschmackstoffen
EP1992344A1 (de) 2007-05-18 2008-11-19 Institut Curie P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
US7973051B2 (en) * 2007-11-30 2011-07-05 Hoffman-La Roche Inc. Aminothiazoles as FBPase inhibitors for diabetes
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
CA2957566C (en) 2014-08-12 2023-08-01 Daniel Paul Becker Indoline sulfonamide inhibitors of dape and ndm-1 and use of the same
PE20221627A1 (es) * 2015-02-16 2022-10-19 Univ Queensland Sulfonilureas y compuestos relacionados y uso de estos
WO2016138473A1 (en) * 2015-02-26 2016-09-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inflammasome activation in myelodysplastic syndromes
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
HK1257569A1 (zh) * 2016-02-16 2019-10-25 The University Of Queensland 磺醯脲和相关化合物及其用途
US11339136B2 (en) 2016-04-18 2022-05-24 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
ES2940611T3 (es) 2016-04-18 2023-05-09 Novartis Ag Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP
EP3272739A1 (de) * 2016-07-20 2018-01-24 NodThera Limited Sulfonylharnstoff-derivate und ihre verwendung in der kontrole der interleukin-1-aktivität
EP3548480A1 (de) * 2016-11-29 2019-10-09 Epizyme, Inc. Verbindungen mit einer sulfonsäuregruppe als kat-inhibitoren
BR112019014549A2 (pt) 2017-01-23 2020-02-18 Genentech, Inc. Compostos de fórmulas i, ig, ih, ie, compostos, composição farmacêutica, métodos de tratamento, de modulação da atividade de um alvo biológico, de inibição da ativação de um inflamassoma e utilização de um composto
AU2017416068A1 (en) * 2017-05-24 2019-10-31 The Provost, Fellows, Foundation Scholars, And Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Novel compounds and uses
US11236045B2 (en) 2017-06-09 2022-02-01 Cadila Healthcare Limited Substituted sulfoximine compounds
US11370776B2 (en) 2017-07-07 2022-06-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
PE20212077A1 (es) 2017-07-07 2021-10-28 Inflazome Ltd Nuevos compuestos sulfonamida de carboxamida
PL3658539T3 (pl) 2017-07-24 2024-07-01 Novartis Ag Związki i kompozycje do leczenia stanów związanych z aktywnością nlrp
TW201910316A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
WO2019034697A1 (en) 2017-08-15 2019-02-21 Inflazome Limited NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US11773058B2 (en) 2017-08-15 2023-10-03 Inflazome Limited Sulfonamide carboxamide compounds
EP3668842A1 (de) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylharnstoffe und sulfonylthioharnstoffe als nlrp3-inhibitoren
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
EP3692020A1 (de) 2017-10-03 2020-08-12 Inflazome Limited Neuartige verbindungen
CN111417622A (zh) 2017-10-17 2020-07-14 诺华炎症研究公司 用于治疗与nlrp活性相关的病症的磺胺类及其组合物
MA50567A (fr) 2017-11-09 2020-09-16 Inflazome Ltd Nouveaux composés de sulfonamide carboxamide
US12221434B2 (en) 2017-11-09 2025-02-11 Inflazome Limited Sulfonamide carboxamide compounds
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
CN108299256B (zh) * 2018-01-09 2019-09-10 武汉大学 一类2,3,4-三羟基苯磺酰胺衍生物及其制备方法和应用
WO2019166633A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Sulfonamide derivates as nlrp3 inhibitors
WO2019166628A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166629A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166632A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
US11834433B2 (en) 2018-03-02 2023-12-05 Inflazome Limited Compounds
WO2020010143A1 (en) 2018-07-03 2020-01-09 Novartis Inflammasome Research, Inc. Nlrp modulators
CR20210022A (es) 2018-07-20 2021-02-18 Hoffmann La Roche Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1
KR20210034588A (ko) * 2018-07-20 2021-03-30 에프. 호프만-라 로슈 아게 인터루킨-1 활성의 저해제로서의 설포닐유레아 화합물
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
JP2021534148A (ja) 2018-08-15 2021-12-09 インフレイゾーム リミテッド 新規スルフォンアミドウレア化合物
CN113056451A (zh) 2018-10-24 2021-06-29 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
JP7488267B2 (ja) 2019-01-14 2024-05-21 ザイダス・ライフサイエンシーズ・リミテッド 新規な置換スルホニル尿素誘導体
US12054461B2 (en) 2019-06-12 2024-08-06 NodThera Limited Sulfonylurea derivatives and uses thereof
US20220378801A1 (en) 2019-06-21 2022-12-01 Ac Immune Sa Novel compounds
JP2022548869A (ja) 2019-09-12 2022-11-22 カディラ・ヘルスケア・リミテッド 新規な置換スルホキシミン誘導体
JP7504234B2 (ja) 2020-06-11 2024-06-21 シーセン ファーマシューティカル カンパニー リミテッド ジメチルスルホキシミン誘導体
EP4168395B1 (de) 2020-06-19 2026-03-25 AC Immune SA Dihydrooxazol- und thioharnstoff- oder harnstoff-derivate die den nlrp3-inflammasom-signalweg modulieren
WO2022022646A1 (zh) * 2020-07-29 2022-02-03 南京明德新药研发有限公司 含硒五元杂芳环化合物
AR123435A1 (es) 2020-09-04 2022-11-30 Nodthera Ltd Derivados de sulfamoil urea que contienen resto alquilo-oxacicloalquilo, y usos de los mismos
ES2948511A1 (es) * 2021-09-08 2023-09-13 Fundacion Para La Investigacion Biomedica Del Hospital Univ De La Princesa Derivados de n-sulfonilureas y su uso terapeutico
WO2023098612A1 (zh) * 2021-12-03 2023-06-08 南京明德新药研发有限公司 二甲基亚磺酰亚胺衍生物的盐型及晶型
WO2023118521A1 (en) 2021-12-22 2023-06-29 Ac Immune Sa Dihydro-oxazol derivative compounds
WO2023156311A1 (en) * 2022-02-15 2023-08-24 F. Hoffmann-La Roche Ag Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivatives
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation
CA3261036A1 (en) 2022-07-14 2024-01-18 Ac Immune Sa Pyrrolotriazine and imidazotriazine derivatives used as NLRP3 inflammatory pathway modulators
JP2025526423A (ja) 2022-07-28 2025-08-13 エーシー・イミューン・エス・アー 新規化合物
WO2025133307A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Heterocyclic modulators of the nlrp3 inflammasome pathway
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法
WO2025153625A1 (en) 2024-01-17 2025-07-24 Ac Immune Sa Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
WO2025153624A1 (en) 2024-01-17 2025-07-24 Ac Immune Sa Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
WO2025163069A1 (en) 2024-01-31 2025-08-07 Ac Immune Sa Novel compounds
CN118638081A (zh) * 2024-05-23 2024-09-13 武汉科技大学 磺酰脲类化合物
WO2025251275A1 (zh) * 2024-06-07 2025-12-11 上海麦克林生化科技股份有限公司 一种新的苄基亚磺酰基吡啶类化合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4586950A (en) * 1982-05-31 1986-05-06 E. I. Du Pont De Nemours & Company Novel phenyl-substituted sulfonamides
US4780125A (en) * 1982-09-01 1988-10-25 Ciba-Geigy Corporation N-phenylsulfonyl-N'-triazinylureas
DE3927369A1 (de) * 1989-08-19 1991-02-21 Bayer Ag Substituierte n-(chinolin-2-yl-methoxy)benzyl-sulfonyl-harnstoffe
US5064851A (en) * 1990-07-24 1991-11-12 Pfizer Inc. 3-(1-substituted-pyrazoyl)-2-oxindole derivatives, compositions and use
US5254589A (en) * 1991-10-15 1993-10-19 Warner-Lambert Company Sulfonyl urea and carbamate ACAT inhibitors
DE4344957A1 (de) * 1993-12-30 1995-07-06 Hoechst Ag Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Herstellungsverfahren und Verwendungsmöglichkeiten pharmazeutischer Präparate auf Basis dieser Verbindungen
CN1038679C (zh) * 1994-12-07 1998-06-10 南开大学 磺酰脲类化合物及其除草用途
HU226462B1 (en) * 1995-02-17 2008-12-29 Hoechst Ag Substituted benzol-sulfonyl-ureas and -thioureas, process for producing them, pharmaceutical compositions containing them, and their use
US6281240B1 (en) * 1997-04-10 2001-08-28 Eli Lilly And Company Diarylsulfonylureas for use in treating secretory diarrhea

Also Published As

Publication number Publication date
TNSN98017A1 (fr) 2005-03-15
UY24861A1 (es) 2000-09-29
PT964849E (pt) 2003-08-29
AP9801190A0 (en) 1998-03-31
CN1127479C (zh) 2003-11-12
MA26468A1 (fr) 2004-12-20
EA199900603A1 (ru) 2000-02-28
US6433009B1 (en) 2002-08-13
KR100324058B1 (ko) 2002-02-16
NO313279B1 (no) 2002-09-09
HUP0000567A2 (hu) 2000-10-28
SK283679B6 (sk) 2003-11-04
CO4920230A1 (es) 2000-05-29
DE69722663T2 (de) 2004-04-29
CA2279186A1 (en) 1998-07-30
CA2279186C (en) 2004-02-24
NO993658L (no) 1999-09-28
TR199901816T2 (xx) 1999-11-22
NZ336248A (en) 2000-10-27
CN1245490A (zh) 2000-02-23
TW515788B (en) 2003-01-01
PE57898A1 (es) 1999-06-11
DE69729762D1 (de) 2004-08-05
DE69729762T2 (de) 2005-07-14
HUP0000567A3 (en) 2002-10-28
AR011093A1 (es) 2000-08-02
ID22223A (id) 1999-09-16
ZA98685B (en) 1999-07-29
DK0964849T3 (da) 2003-08-25
ES2198598T3 (es) 2004-02-01
NO993658D0 (no) 1999-07-28
EP0964849B1 (de) 2003-06-04
CZ293173B6 (cs) 2004-02-18
WO1998032733A1 (en) 1998-07-30
AU5234098A (en) 1998-08-18
DE69722663D1 (de) 2003-07-10
HRP980045B1 (en) 2002-10-31
AP929A (en) 2001-01-18
PT1270565E (pt) 2004-09-30
EA001803B1 (ru) 2001-08-27
DZ2407A1 (fr) 2003-01-04
EP0964849A1 (de) 1999-12-22
KR20000070541A (ko) 2000-11-25
JP3573757B2 (ja) 2004-10-06
ES2222426T3 (es) 2005-02-01
IS5099A (is) 1999-06-29
OA11079A (en) 2002-03-14
PA8444701A1 (es) 2000-05-24
BR9714328A (pt) 2000-03-21
ATE270285T1 (de) 2004-07-15
SK98299A3 (en) 2001-10-08
YU33799A (sh) 2002-03-18
US6166064A (en) 2000-12-26
JP2000511200A (ja) 2000-08-29
AU723895B2 (en) 2000-09-07
HRP980045A2 (en) 1999-06-30
BG103597A (bg) 2000-02-29
IL130855A0 (en) 2001-01-28
PL335052A1 (en) 2000-03-27
DK1270565T3 (da) 2004-10-04
CZ257599A3 (cs) 2000-09-13

Similar Documents

Publication Publication Date Title
ATE242208T1 (de) Sulfonylharnstoff-derivate und ihre verwendung in der kontrolle der interleukin-1-aktivität
DE69528342D1 (de) Teilchenförmige Schaumkontrollmittel und ihre Verwendung
EP1006990A4 (de) Haarfärbemittel und ihre verwendung
DE69805515D1 (de) Aminophenolderivate und ihre verwendung in der kosmetik
DE59704640D1 (de) Sulfonamide und ihre Verwendung
NO982884D0 (no) Fenyl- og aminofenyl-alkylsulfonamid og ureaderivater
DE59806989D1 (de) Laseretiketten und ihre Verwendung
ATE375987T1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
DE69819106D1 (de) Haarfärbemittel und verwendung
DE59710422D1 (de) Acylmercapto-triazolyl-derivate und ihre verwendung als mikrobizide
DE69826662D1 (de) 4-brom or 4-iod-phenylamino-benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren
ATE344246T1 (de) Heteroaryl aminoguanidin- und alkoxyguanidinderivate und ihre verwendung als proteasehemmer
DE69617236D1 (de) N-heteroaryl-pyridinsulfonamidderivate und deren verwendung als endothelinantagonisten
DE59710579D1 (de) Sulfonyl-mercapto-triazolyl-derivate und ihre verwendung als mikrobizide
DE59805492D1 (de) Laseretiketten und ihre Verwendung
DE69826693D1 (de) Amidinoderivate und ihre verwendung als thrombininhibitoren
NO970087D0 (no) Urea- og tiourea-azolonderivater med anti-Helicobacteraktivitet
DE69716062D1 (de) Benzofuran-derivate und deren verwendung
EP0973389A4 (de) Stickstoff enthaltende oxyalkylen-ester und ihre verwendung
DE59603788D1 (de) 1-fluorisochinolinderivate und ihre verwendung in flüssigkristallinen mischungen
DE50008549D1 (de) Triazolotriazinone und ihre verwendung
DE59603787D1 (de) 1-fluor-6,7-dihydro-5h-isochinolin-8-on-derivate und ihre verwendung in flüssigkristallinen mischungen
DE69811018D1 (de) Triazol-Derivate und ihre Verwendung als antimykotische Mittel
EP1073458A4 (de) Chlamydia proteine und ihre verwendung
DE69521174D1 (de) Anthrachinonderivate mit antitumorwirkung und ihre verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0964849

Country of ref document: EP

REN Ceased due to non-payment of the annual fee